Microbial antigen mimics activate diabetogenic CD8 T cells in NOD mice

Ningwen Tai,1 Jian Peng,1 Fuqiang Liu,1,2 Elke Gulden,1 Youjia Hu,1 Xiaojun Zhang,1 Li Chen,2 F. Susan Wong,3 and Li Wen1

Both animal model and human studies indicate that commensal bacteria may modify type 1 diabetes (T1D) development. However, the underlying mechanisms by which gut microbes could trigger or protect from diabetes are not fully understood, especially the interaction of commensal bacteria with pathogenic CD8 T cells. In this study, using islet-specific glucose-6-phosphatase catalytic subunit–related protein (IGRP)–reactive CD8 T cell receptor NY8.3 transgenic nonobese diabetic mice, we demonstrated that MyD88 strongly modulates CD8+ T cell–mediated T1D development via the gut microbiota. Some microbial protein peptides share significant homology with IGRP. Both the microbial peptide mimic of Fusobacteria and the bacteria directly activate IGRP–specific NY8.3 T cells and promote diabetes development. Thus, we provide evidence of molecular mimicry between microbial antigens and an islet autoantigen and a novel mechanism by which the diabetogenicity of CD8+ T cells can be regulated by innate immunity and the gut microbiota.

INTRODUCTION

Type 1 diabetes (T1D) is an autoimmune disease characterized by T cell–mediated destruction of insulin-producing pancreatic β cells (Bluestone et al., 2010). Interacting genetic and environmental factors eventually lead to the loss of functional β cell mass and hyperglycemia (Bluestone et al., 2010; Polychronakos and Li, 2011; Nielsen et al., 2014). The discordant diabetes incidence in monozygotic twins (<50% developed T1D) strongly suggests that nongenetically determined factors regulate T1D development (Kaprio et al., 1992). Recent studies in mouse models and humans have shown that gut microbiota play an important role in disease development.

We previously showed that commensal bacteria modified diabetes development in nonobese diabetic (NOD) mice via myeloid differentiation primary response 88 (MyD88). Specific pathogen–free MyD88–deficient (MyD88−−) NOD mice were protected from T1D development, whereas germ-free MyD88−−/− NOD mice developed normal diabetes (Wen et al., 2008). Gender bias in T1D in NOD mice is influenced by microbiota (Markle et al., 2013; Yurkovetskiy et al., 2013). Studies in humans also indicate that the gut microbiome plays an important role in T1D development. Gut microbial communities in high-risk children are characterized as less diverse, distinct from those of healthy controls (Brown et al., 2011; Kostic et al., 2015). Furthermore, a low abundance of lactate– and butyrate–producing bacteria, reduced Bifidobacterium species, and increased bacteria of the Bacteroides genus were found in islet autoantibody–positive children (de Goffau et al., 2013). Individuals with islet autoantibodies, sero-negative first-degree relatives, and new-onset patients had different abundances of Lactobacillus and Staphylococcus (both Firmicides) compared with healthy control subjects (Alkanani et al., 2015). Thus, altered gut microbiota are associated with β cell autoimmunity in humans at risk of developing T1D, underscoring a role for gut microbiota in the pathogenesis of islet cell autoimmunity and T1D development.

CD8+ T cells play an important role in the development of T1D in both NOD mice and humans (Wong et al., 1999, 2009; Liblau et al., 2002; Lieberman et al., 2003; Tsai et al., 2008). CD8+ T cells predominate in islet infiltrates in patients with T1D (Willcox et al., 2009), and islet autoantigen–specific CD8+ T cell clones were generated from the peripheral blood of T1D patients (Peakman et al., 1994; Unger et al., 2007; Skowera et al., 2008). Other studies have demonstrated heightened expression of MHC class I and CD8+ T cells in the islets of patients with T1D (Foulis et al., 1987; Coppieters et al., 2012; Pugliese et al., 2014; Rodriguez-Calvo et al., 2015). However, there is a substantial gap in our knowledge of how islet autoimmunity mediated by CD8+ T cells is shaped by innate immunity and the gut microbiota. To investigate the link of innate immunity and gut microbiota to CD8+ T cells in T1D development, we generated MyD88−−/−/NOD mice car...
rering diabetogenic CD8 TCR NY8.3, specific for islet-specific glucose–6-phosphatase catalytic subunit–related protein (IGRP; Verdaguer et al., 1997; Lieberman et al., 2003). To our surprise, the mice developed highly accelerated diabetes with altered gut microbiota enriched in *Fusobacteria* that express a magnesium transporter (Mgt) encompassing a microbial peptide mimic of IGRP. The mimic peptide directly activated IGRP-specific CD8 T cells and, importantly, induced robust diabetes in vivo. Supercolonization of the mice with this strain of bacteria accelerated diabetes in NY8.3NOD mice. Lastly, increased fecal *Fusobacteria* were also associated with diabetes progression in NOD mice. Therefore, our study provides direct evidence that molecular mimicry by microbial peptides of islet autoantigen contributes to T1D.

**RESULTS**

**Accelerated diabetes in MyD88−/−NY8.3NOD mice is MyD88 dependent, IGRP reactive, and TCR specific**

To better understand the interplay among innate immunity, gut microbes, and diabetogenic CD8 T cells, we generated several lines of TLR-deficient (TLR−/−) and MyD88−/− NY8.3NOD mice. TLR2−/− and male TLR9−/−NY8.3 mice had significantly delayed diabetes onset (Fig. 1, A and D), whereas TLR4−/−, TLR5−/−, and female TLR9−/−NY8.3 mice were not affected by the loss of these TLRs (Fig. 1, B–D). In contrast, MyD88−/−NY8.3 mice (both sexes) developed markedly accelerated diabetes (Fig. 1 E). This also contrasts with the protected phenotype in polyclonal MyD88−/−NOD mice in specific pathogen-free conditions (Wen et al., 2008). Interestingly, there was no gender difference in diabetes incidence in either WT NY8.3NOD or MyD88−/−NY8.3NOD mice (not depicted). Collectively, our data suggest that the accelerated diabetes in MyD88−/−NY8.3NOD mice is MyD88 dependent.

**CD8 T cells are more activated in MyD88−/−NY8.3 mice**

We next examined the phenotype and function of NY8.3 CD8 T cells. MyD88 deficiency does not affect thymic selection of NY8.3 T cells (Fig. 2 A); however, the number of splenic CD8 T cells was lower in MyD88−/−NY8.3NOD mice compared with the NY8.3NOD mice (Fig. 2 B). There were no differences in the number of CD8 T cells in pancreatic LN or mesenteric LN (MLN; not depicted). In contrast, we found more CD8 T cells in islet infiltrates of MyD88−/−NY8.3NOD mice compared with WT NY8.3NOD mice (Fig. 2 C). Furthermore, there was no difference in Foxp3+CD4 T regulatory cells in the lymphoid tissues examined (Fig. 2 D), but there were more activated (CD69+) and memory/effector (CD62Llow/CD44high) NY8.3 CD8 T cells in MyD88−/− hosts (Fig. 3, A and B). CD8 T cells from MyD88−/−NY8.3NOD mice also showed stronger responses to their native autoantigen, IGRP, and expressed more granzyme B upon anti-CD3 stimulation in vitro, compared with WT mice (Fig. 3, C and D). Importantly, they induced more aggressive diabetes in vivo (Fig. 3 E).

These data demonstrated that MyD88 deficiency resulted in stronger activation of CD8 T cells in NY8.3NOD mice.

**MyD88 deficiency changes gut microbiota composition in NY8.3 mice and modifies diabetes development**

We tested whether MyD88 deficiency also affected the composition of gut microbiota in MyD88−/−NY8.3NOD mice as in polyclonal NOD mice (Wen et al., 2008) by 16S rRNA pyrosequencing of the fecal samples from MyD88−/− and WT NY8.3NOD mice. MyD88 deficiency indeed altered gut microbiota composition (Fig. 4, A–C) with a much greater α and β diversity in the bacterial community of MyD88−/−NY8.3NOD mice compared with WT NY8.3NOD mice (Fig. 4, D and E). *Actinobacteria, Bacteroidetes*, and *Proteobacteria* were increased, and *Firmicutes* was reduced at the phylum level, whereas *Lactobacillus* was significantly less abundant at the genus level in MyD88−/−NY8.3NOD mice compared with WT NY8.3NOD mice.

Next, we quantified the levels of antimicrobial peptides, which affect gut bacterial growth, in the intestines. Expression of Reg3β, Reg3γ, RELMβ, and C-reactive protein–ductin were reduced in MyD88−/−NY8.3NOD mice (Fig. 5, A and B), which may have contributed to the altered gut microbiome in MyD88−/−NY8.3NOD mice, affecting diabetes development.

**Manipulation of gut microbiota alters diabetes development in MyD88−/−NY8.3NOD mice**

To test whether the altered gut microbiota in MyD88−/−NY8.3NOD mice was responsible for the accelerated diabetes, we cohoused the MyD88−/−NY8.3NOD mice with WT NOD mice. Remarkably, ~80% of MyD88−/−NY8.3NOD mice were completely protected from diabetes development when cohoused with age- and sex-matched WT NOD mice (Fig. 6 A). This cohousing neither changed the activation of CD4 or CD8 T cells nor affected the insulitis in WT NOD mice (not depicted), and there was no modulation of the diabetes development in WT NOD mice (not depicted). This implies that the WT microbiota had a dominant effect on the MyD88−/−NY8.3NOD mice rather than vice versa. As a control, we also cohoused WT NY8.3NOD mice with WT NOD mice, which did not affect diabetes incidence in WT NY8.3NOD (not depicted). To test whether the protected phenotype was horizontally transferable to a second host, we performed fecal transfer by orally gavaging the fecal suspension from diabetes-free cohoused MyD88−/−NY8.3NOD mice to another set of naïve MyD88−/−NY8.3NOD mice. Interestingly, oral transfer (OT) of gut microbes from diabetes-protected MyD88−/−NY8.3NOD donors conferred even greater protection against diabetes, accompanied by a marked reduction in insulitis (Fig. 6, B and C) and an alteration of gut microbiota α-diversity, β-diversity, or composition ascertained by 16S rRNA pyrosequencing (Fig. 6, D–G). Interestingly, in the mice...
Figure 1. MyD88 deficiency has different effect on diabetes development. (A–E) Individual TLR- or MyD88−/− NY8.3NOD mice were generated by breeding different TLR−/− or MyD88−/− NOD mice with NY8.3 NOD mice. Diabetes development was observed, and data were pooled from at least five independent experiments. (A) TLR2−/− NY8.3. (B) TLR4−/− NY8.3. (C) TLR5−/− NY8.3. (D) TLR9−/− NY8.3. (E) MyD88−/− NY8.3. Wilcoxon test for survival was used for analysis of diabetes incidence. *, P < 0.05; **, P < 0.01; ***, P < 0.001. F, female. M, male.
that were protected from diabetes by cohousing or fecal transfer, there was a clear reduction in Bacteroidetes and an increase of Firmicutes at the phylum level of the microbiota community in MyD88<sup>−/−</sup>NY8.3 mice compared with the control counterparts (Fig. 6 F). To investigate whether the protected phenotype was vertically transferable to the next generation, we used horizontally protected MyD88<sup>−/−</sup>NY8.3NOD mice as breeders and observed diabetes development in their progeny. Strikingly, the disease protection was indeed vertically transferable (Fig. 6 H). Collectively, our data suggest that MyD88 deficiency in NY8.3NOD mice results in dysbiosis of the gut microbiota, leading to accelerated diabetes. However, cohousing completely reversed the diabetic phenotype, and importantly, diabetes protection was transferable to new hosts and to the next generation.

**Microbial mimic peptides can stimulate diabetogenic CD8<sup>+</sup> T cells in vitro and induce diabetes in vivo**

To probe the mechanism by which dysbiosis of gut commensals, in the absence of MyD88, leads to highly accelerated
diabetes development in NY8.3NOD mice, we hypothesized that gut bacterial products may activate NY8.3 CD8+ T cells. We compared the IGRP206–214 peptide sequence against bacterial protein sequences in the nonredundant protein sequence database and found several peptides from oral or gut bacteria that share strong homology with IGRP206–214, the native autoantigen of NY8.3 CD8+ T cells (Table 1). Three of these IGRP mimic peptides, designated as W15944, W15946, and W15948, activated NY8.3 CD8+ T cells with a comparable potency with IGRP native peptide using: (a) proliferation of NY8.3 CD8+ T cells (Fig. 7 A), (b) IFN-γ production, and (c) induction of granzyme B (Fig. 7 B). Furthermore, all the responses were restricted by MHC class I–Kd (Fig. 7, C and D). Importantly, the microbial mimic peptides, which activated NY8.3 CD8+ T cells, induced these NY8.3 CD8+ T cells to rapidly transfer diabetes in vivo (Fig. 7 E). The peptide mimic W15945 was not stimulated NY8.3 CD8+ T cells in vitro (Fig. 7 A) and did not induce diabetes in vivo (not depicted). Comparatively, W15944 stimulated the NY8.3 T cells most strongly both in vitro and in vivo (Fig. 7, A, B, and E). When compared with IGRP206–214, W15944 induced stronger CTL function of NY8.3 CD8+ T cells in vitro and similar diabetogenicity in vivo (Fig. 7, F and G). W15944-, W15946-, and W15948-activated CD8+ T cells from MyD88−/−NY8.3NOD mice all induced significantly higher diabetes incidence in irradiated young NOD mice compared with their WT counterparts that were activated in parallel (Fig. 7, H–J). 100% of NOD recipients developed diabetes by day 6 after adoptive transfer of W15944-activated MyD88−/−NY8.3 CD8+ T cells (Fig. 7 J). Furthermore, immunization with W15944 induced significantly accelerated diabetes in WT NY8.3NOD mice compared with IGRP206–214 or CpG alone (Fig. 7 K). To further test that the microbial peptides specifically stimulated NY8.3 CD8+ T cells, we stimulated insulin-reactive G9 CD8+ T cells with the mimic peptides. As expected, all the microbial peptides tested failed to activate G9 CD8+ T cells that are specific for insulin B15–23 (Wong et al., 1996, 2009), suggesting the specificity of the microbial peptides to IGRP (Fig. 7 L). Collectively, our data strongly suggest that microbial antigen mimics can act as agonists that not only activate islet antigen–specific pathogenic CD8+ T cells in vitro, but also induce robust diabetes in vivo.

Increased abundance of Fusobacteria and Leptotrichia goodfellowii is associated with accelerated diabetes

The microbial peptide mimic W15944 derives from an Mgt (GenePept accession no.WP_006806773) of L. goodfellowii, a member of the phylum Fusobacteria (gram-negative an-
Fusobacteria are associated with inflammatory disorders including skin ulcers (Legaria et al., 2005) and inflammatory bowel diseases (Ohkusa et al., 2003; Strauss et al., 2011). We found that the Fusobacteria represent <0.1% of sequencing reads of fecal samples of MyD88−/−NY8.3NOD and WT NY8.3NOD mice. To quantify the presence of Fusobacteria or L. goodfellowii, we performed quantitative PCR (qPCR) with specific primers using bacterial DNA from fecal and oral samples of prediabetic MyD88−/−NY8.3NOD and sex- and age-matched WT NY8.3NOD mice.

MyD88−/−NY8.3NOD mice harbored significantly more Fusobacteria in both fecal and oral samples and more L. goodfellowii in oral samples (Fig. 8A). Interestingly, a significant reduction of the abundance of Fusobacteria was observed in the fecal samples of the protected cohoused or orally transferred MyD88−/−NY8.3NOD mice compared with control mice, indicating that the reduced abundance of Fusobacteria could be associated with the reduced diabetes incidence in these mice (Fig. 8B).

Next, we investigated whether the abundance of Fusobacteria is associated with diabetes development in WT NOD...
mice. We found a significantly higher abundance of *Fusobacteria* in the fecal samples of new-onset diabetic compared with age-matched nondiabetic female NOD mice (Fig. 8 C). Furthermore, we collected serial fecal samples from 6–wk-old female NOD mice until diabetes onset. Of note, we observed a significant increase in the abundance of *Fusobacteria* in the fecal samples from prediabetic (13–16 wk old) compared with young mice (no insulitis 6 wk or mid-insulitis 10 wk), indicating a possible role of *Fusobacteria* in diabetes development, as these mice all became diabetic later (Fig. 8 D). Collectively, these data suggest a possible association between the abundance of *Fusobacteria* and diabetes development.

*L. goodfellowii* activates NY8.3 CD8+ T cells in vitro and accelerates diabetes in WT NY8.3NOD mice in vivo

As the peptide mimic W15944 exerted pathogenic effects by strongly stimulating NY8.3 CD8+ T cells in vitro and inducing rapid diabetes in vivo, we tested whether APCs can process and present W15944 from *L. goodfellowii*. First, we stimulated splenocytes from MyD88−/− or WT NY8.3NOD mice with the whole cell lysates of *L. goodfellowii*. *Bacteroides thetaiotaomicron* (*B. theta*), also a gram-negative anaerobe, was used as a control. Bacterial lysates of *L. goodfellowii* induced significantly higher expression of IFN-γ in NY8.3 CD8+ T cells compared with WT NY8.3 NOD CD8+ T cells compared with WT NY8.3NOD CD8+ T cells (Fig. 9 A). This was confirmed using purified BMDCs or enriched APCs from spleens and gut-associated lymphoid tissue (GALT), including MLN and Peyer’s patches (PP), of NOD mice (not depicted). Second, using a cell-free *Escherichia coli* S30 extraction system to express recombinant Mgt (rMgt) protein, we stimulated NY8.3 CD8+ T cells and induced a significantly larger amount of MIP-1β (early CD8+ T cell activation indicator) production compared with the negative control, *E. coli* S30 with an empty vector (Fig. 9 B). We also used truncated rMgt protein as an antigen in the stimulation assay. CD8+ T cells from both WT NY8.3 NOD and MyD88−/−NY8.3NOD mice responded strongly to the antigen presented by purified NOD splenic APCs (Fig. 9 C). Third, we tested the capacity of GALT APCs, in vitro pulsed with *L. goodfellowii*, to process and present the IGRP mimic in the absence of exogenous antigen. *L. goodfellowii*–pulsed GALT APC induced significantly higher expression of IFN-γ and TNF by NY8.3 CD8+ T cells than those pulsed with *B. theta* (Fig. 9 D). Fourth, we supercolonized 2–3-mo-old female NOD mice by oral gavage with either *L. goodfellowii* or *B. theta* daily for five consecutive days. Splenic or GALT APCs from the *L. goodfellowii*–gavaged NOD mice readily induced a significantly larger amount of MIP-1β and a higher expression of IFN-γ in NY8.3 CD8+ T cells compared with the splenic or GALT APCs from *B. theta*–treated mice (Fig. 9, E and F). To further confirm the specific recognition of *L. goodfellowii* by NY8.3 CD8+ T cells, we tested two more bacterial strains, *Bacteroides dorei* and *Lactobacillus reuteri*, in addition to *B. theta*. All the strains tested, except *L. goodfellowii*, failed to stimulate NY8.3 CD8+ T cells (Fig. 9 G). Finally, we orally gavaged the young WT NY8.3NOD mice with *L. goodfellowii* or *B. theta* to test the diabetogenicity directly. The supercolonization of *L. goodfellowii* significantly accelerated diabetes development in WT NY8.3NOD mice compared with *B. theta*–colonized mice or untreated WT NY8.3NOD mice (Fig. 9 H). Collectively, these data demonstrated that *L. goodfellowii*, as well as the purified Mgt protein, can be processed by splenic or GALT APCs from NOD mice to stimulate the NY8.3 cells. Most importantly, the bacteria can trigger early onset of diabetes.

**DISCUSSION**

In this study, we present evidence that a transporter protein peptide from a strain of *Fusobacteria* can be processed and presented by gut-associated antigen-presenting cells and stim-
Figure 6. Manipulation of gut microbiota protects from diabetes development in MyD88−/−NY8.3 mice. (A) Diabetes incidence in MyD88−/−NY8.3NOD mice after 4-wk-old MyD88−/−NY8.3NOD mice were cohoused with an equal number and age- and sex-matched NOD mice. F, female; M, male. (B) Diabetes development of MyD88−/−NY8.3NOD mice after fecal OT. The fresh gut bacteria (~10^8–10^9 culturable bacteria/mouse) from diabetes-free cohoused MyD88−/−NY8.3 mice (from A) were fed orally to sex-matched 4-wk-old naive MyD88−/−NY8.3NOD mice. (C) Insulitis of MyD88−/−NY8.3NOD mice after cohousing with WT NOD mice or OT (from A and B). More than 120 islets from five to six treated mice/group were examined. Representative pancreatic sections are shown on the left, and the summary of the insulitis scores is shown on the right. χ^2 test was used for analysis. (D) α-Diversity of gut microbiota is shown by Chao richness. Fecal samples from the control, cohoused, and OT MyD88−/−NY8.3NOD mice were used for taxonomic analysis by 16S rRNA.
ulate IGRP-reactive CD8 T cells to accelerate diabetes. These bacteria are increased in the gut microbiome in the absence of MyD88. Using IGRP-reactive NY8.3 TCR transgenic mice as a model, MyD88−/−NY8.3NOD mice developed highly accelerated diabetes. The gut microbiota play a critical role in the disease acceleration, confirmed by disease reduction when the gut microbiome are altered via cohousing or fecal transfer from nondiabetes-accelerated mice. Moreover, supercolonization with the live bacteria or immunization with the microbial peptide in NY8.3 mice accelerated diabetes, and importantly, these bacteria also increase in polyclonal NOD mice during diabetes progression and at diabetes onset.

Although there are several studies showing gut commensals influence autoimmunity, none have demonstrated direct influence through stimulation of the autoreactive T cells in diabetes. Molecular mimicry has long been suggested as a pathogenic mechanism for the development of T1D, but to date, although demonstrated in some autoimmune diseases, there has been no convincing direct evidence for T1D. To probe the mechanism, a defined setting is required. We used TCR transgenic mice that develop spontaneous diabetes, allowing us to study the known TCR clonotypes and the possible mimic agonists. The NY8.3 cells are highly promiscuous as demonstrated by the initial difficulty of identifying the autoantigen by the screening of a peptide library (Anderson et al., 1999), and indeed this is the case for many low-affinity autoreactive T cells (Wooldridge et al., 2012). This promiscuity of T cell antigen recognition makes it likely that more than one naturally occurring peptide product can stimulate the T cells, implying that the gut bacteria could be a particularly rich source of potential antigens. Several microbial peptides are highly homologous to islet autoantigen IGRP (206–214), the ligand of NY8.3 TCR, and can stimulate the diabetogenic NY8.3 cells. One of these is from the Mpt protein of L. goodfellowii, a strain of Fusobacteria, enriched in the MyD88−/−NY8.3NOD mice. IGRP is a key target for diabetogenic CD8 T cells in both the NOD mouse as well as in humans (Lieberman et al., 2003; Jarchum et al., 2008; Ko et al., 2014). NY8.3-like CD8 T cells increase in NOD mice with increasing avidity for their target antigen along with the progression to diabetes development in unmanipulated NOD mice (Amrani et al., 2000), and this coincides with the increase of fecal Fusobacteria in NOD mice shown in this study. To our knowledge, this is the first direct demonstration of a specific gut bacterium to stimulate a TCR, that increases in avidity with time.

Previous studies have shown TCR cross-reactivity between MHC II–binding self-antigen and foreign peptides including microbial products, which could cause autoimmunity by stimulating autoreactive T cells (Birnbaum et al., 2014; Horai et al., 2015; Nelson et al., 2015). Most interestingly, a newly published study used a human CD8+ T cell clone (1E6), which is MHC class I restricted and human preproinsulin reactive, to generate high-resolution structures of the 1E6 TCR bound to seven altered peptide ligands, including a microbe-derived peptide (Cole et al., 2016). The authors found that this clonal TCR could stably and functionally bind with multiple peptide-major histocompatibility complexes through a conserved lock-and-key–like minimal binding footprint. This enables 1E6 TCR to tolerate vast numbers of substitutions outside of these so-called hotspots, which were found in foreign antigens compared with the natural autoimmune ligand, indicating that T cell cross-reactivity with microbe-derived antigens could break self-tolerance to induce autoimmune disease. Viral proteins with homology to autoantigens have been identified in diabetes. However, there is no direct evidence of their diabetogenicity. It is important to show that not only is this a theoretical possibility, but also that the microbial peptides can actually be processed and presented appropriately and that there is a direct interaction of the bacteria with the autoreactive T cells. Our data clearly demonstrated that bacterial lysates as well as the purified protein from the L. goodfellowii could be processed by DCs and GALT APC and presented the IGRP mimetic peptides to NY8.3 T cells inducing inflammatory chemokine or cytokine MIP-1β, IFN-γ, and TNF production. Most importantly, we have shown that after supercolonizing the mice with L. goodfellowii, the extracted GALT APC stimulated NY8.3 cells in the absence of exogenous antigen. This clearly demonstrated that not only could the peptide be processed by APC in vitro, but also that the L. goodfellowii in the gut could be presented to NY8.3 cells in vivo.

Ultimately, however, the question arises as to whether these bacteria could have a direct effect on diabetes in vivo, as this is a major test of whether these bacteria have physiological and/or immunological relevance. We have shown this in several ways. First, immunizing NY8.3 TCR transgenic mice with the bacterial mimic peptide accelerated spontaneous diabetes, demonstrating the ability of this particular peptide to be presented in vivo and activate IGRP reactive cells to induce disease. Second, we have shown that disease acceleration can occur by increasing L. goodfellowii after su-
percolonization of the bacteria in the gut, indicating that the bacterial proteins and peptides can be presented in vivo to the IGRP-reactive T cells in the NY8.3 mice.

The gut microbiota comprises a large number of genera of bacteria that are very sensitive to the environment, including influences from diet, water, and antibiotics. Host factors including MyD88, a key adaptor for innate immunity, are also important (Wen et al., 2008). Identifying commensal gut bacteria that could trigger or increase autoreactive responses will considerably advance our understanding of environmental influences in pathogenesis of disease and provide important targets for therapy. The increase in Fusobacteria in the MyD88−/−NY8.3NOD mice increases the abundance of the bacterial protein peptide that can stimulate the NY8.3 T cells. When the gut microbiota composition in MyD88−/−NY8.3NOD mice was altered through cohousing or fecal transfer, this completely reversed the diabetes acceleration in MyD88−/−NY8.3NOD mice and was associated with the reduction of the Fusobacteria. Moreover, L. goodfellowii, a strain of Fusobacteria, can directly stimulate IGRP-reactive T cells in this pathogenic process. Fusobacteria are normally present in low abundance in NOD mice; however, there was a strong correlation between the abundance of Fusobacteria and progression to diabetes in polyclonal NOD mice. Furthermore, there were also significantly more Fusobacteria in diabetic NOD mice compared with the age- and gender-matched nondiabetic NOD littermates. Thus, the expansion of NY8.3-like CD8 T cells correlates with an increase in gut Fusobacteria and could conceivably be caused by the increase of Fusobacteria. It should be noted that IGRP-reactive T cells are not the only autoreactive CD8 T cells involved in the development of diabetes, and there is heterogeneity of early abundance of different TCR clonotypes (Lieberman et al., 2004). Furthermore, IGRP reactivity is dependent on an autoimmune response to insulin (Krishnamurthy et al., 2006, 2008), but these cells also increase in avidity and abundance with time (Amrani et al., 2000). Thus, it is likely, in the polyclonal setting, that other factors will also interact to increase the abundance of these bacteria or other microbial antigens to contribute to the development of diabetes. Fusobacteria have been reported to be associated with inflammatory disorders including inflammatory bowel diseases (Ohkusa et al., 2003; Strauss et al., 2011), whether Fusobacteria are also associated with human T1D development remains to be elucidated.

The increase of Firmicutes and decrease of Bacteroidetes are correlated with delay of or protection from diabetes development in our current study, which support the findings in other animal models and/or human studies (Giongo et al., 2011; de Goffau et al., 2013; Murri et al., 2013; Wolf et al., 2014). However, our previous study using non-TCR transgenic MyD88−/−NOD mice showed a lower ratio of Firmicutes/Bacteroidetes, suggesting that T cell repertoire may play a role in the composition of gut microbiota of the host (Wen et al., 2008). It is not clear, at this stage, how the T cell repertoire affects the bacterial community and the possible biological consequences. However, it is clear that changing gut microbiota will have a significant impact on T1D development.

Our study therefore, provides direct evidence of molecular mimicry of microbial peptides with islet autoantigen and a novel mechanism by which the diabetogenicity of CD8+ T cells can be regulated by innate immunity and the gut microbiota in T1D. We believe that these data will be not only of great interest to investigators involved in studies of the pathogenesis and therapy of T1D, but also will be of general importance in providing evidence that molecular mimicry, originating in the gut microbiome, can indeed be a causative factor in the development of autoimmune disease.

**MATERIALS AND METHODS**

**Mice**

NOD/Caj mice have been maintained at Yale University for >25 yr. TLR2−/−NOD, TLR4−/−NOD, TLR9−/−NOD, and MyD88−/−NOD mice were generated as previously described (Wen et al., 2008; Wong et al., 2008). TLR5−/−NOD was generated by backcrossing TLR5−/−C57BL/6 (provided by R. Flavell, Yale University, New Haven, CT) with NOD mice for >12 generations. NY8.3NOD mice (The Jackson Laboratory) were bred with TLR or MyD88-deficient NOD mice to obtain TLR2−/−NY8.3, TLR4−/−NY8.3, TLR5−/−NY8.3, TLR9−/−NY8.3, and MyD88−/−NY8.3NOD mice. G9C−/−NOD mice were generated as reported previously (Wong et al., 2009). All the mice were kept in specific pathogen-free conditions in a 12-h dark/light cycle and housed in individually ventilated filter cages with autoclaved food and bedding. The use of animals and all procedures were approved by the Institutional Animal Care and Use Committee of Yale University and the Home Office, Wales, UK.

---

Table 1. The origin and sequence of the peptides used in the study

<table>
<thead>
<tr>
<th>Name of the peptides</th>
<th>Protein name</th>
<th>Origin</th>
<th>Position</th>
<th>Peptide sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGRP</td>
<td>IGRP</td>
<td>Mouse</td>
<td>206–214</td>
<td>VYLKTNVFL</td>
</tr>
<tr>
<td>W15944</td>
<td>Mgt</td>
<td>L. goodfellowii (gram negative, mainly oral cavity)</td>
<td>267–275</td>
<td>TLYLTKNFVFT</td>
</tr>
<tr>
<td>W15945</td>
<td>glycosyl transferase, group 2</td>
<td>uncultured Flavobacteria bacterium (gram negative, commensal)</td>
<td>303–311</td>
<td>FYLKTSSVFL</td>
</tr>
<tr>
<td>W15946</td>
<td>hypothetical protein IEM_00289</td>
<td>Bacillus cereus (gram positive, gut flora)</td>
<td>252–260</td>
<td>VYLKVNFK</td>
</tr>
<tr>
<td>W15948</td>
<td>NAD synthetase</td>
<td>Enterobacter mori LMG 25706 (gram negative)</td>
<td>32–40</td>
<td>SYLKTNAFL</td>
</tr>
</tbody>
</table>

Bold letters represent the amino acids different from those in the same positions in the control IGRP peptide.
Figure 7. **Microbial peptide mimics can activate NY8.3 CD8+ T cells in vitro and induce diabetes in vivo.**

(A) NY8.3 CD8+ T cell response to microbial peptide mimics shown in proliferation assay by [3H]thymidine incorporation. The experiment was repeated at least four times. (B) Representative FACS plots for expression of granzyme B (GzmB) and IFN-γ in NY8.3 CD8+ T cells stimulated with mimic peptides or IGRP206–214 peptide (1 µg/ml). Student’s t test was used for statistical analysis to compare individual peptide mimics with IGRP206–214 peptide. Data are representative of four independent experiments. n ≥ 10.

(C) MHC class I blocking assay. Two-tailed Student’s t test was used for statistical analysis. n = 3/group/experiment, and the experiment was performed three times. (D) MHC restriction assay. n = 3/group/experiment, and the experiment was performed twice. Two-way ANOVA with Bonferroni correction was used for analysis. (E) Diabetes development induced by NY8.3 CD8+ T cells activated with microbial peptide mimics from two independent experiments. Log-rank test for survival was used. (F) CTL activity of CD8+ T cells induced by W15944 peptide. Two-way ANOVA with Bonferroni correction was used for analysis. n = 4/group/experiment, and the experiment was performed three times. (G) Pathogenic effect of W15944-stimulated NY8.3 CD8+ T cells. Log-rank test for survival was used for statistical analysis. The results are from two independent experiments (n = 5/group/experiment). [H–J] MyD88+NY8.3 and WT NY8.3NOD CD8 T cells activated by microbial peptide mimics induced diabetes by adoptive transfer into irradiated NOD mice. The experiments were repeated twice. (H) W15946. (I) W15948. (J) W15944. Log-rank test for survival was used for analysis. (K) Incidence of diabetes in WT NY83.NOD mice after immunization with mimic peptide from L. goodfellowii. The data were pooled from two independent experiments. Log-rank test for survival was used for analysis. (L) Response of insulin-specific G9 T cells to the microbial peptides. (Left) Granzyme B. (Right) IFN-γ. n = 2/group/experiment, and the experiment was performed twice. One-way ANOVA was used for statistical analysis. Data are mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ***** P < 0.00001.
Antibodies and reagents
All the fluorochrome-conjugated mAbs used in this study were purchased from eBioscience or BioLegend unless otherwise stated. Hybridoma supernatants containing mAbs, used for cell purification or stimulation, were generously provided by C. Janeway Jr. (Yale University). Magnetic beads conjugated with goat anti–mouse IgG, goat anti–mouse IgM, or goat anti–rat IgG were purchased from QIAGEN. RPMI 1640 medium and heat-inactivated FCS were purchased from Invitrogen and Gemini, respectively.

Isolation of infiltrated immune cells from islets
The pancreata were removed from 6–7-wk-old MyD88−/−NY8.3NOD or WT NY8.3NOD mice and incubated with 10 ml HBSS containing 10 mM Hepes and 1.5 mg/ml collagenase V (Sigma-Aldrich) at 37°C for 12 min with vigorous shaking. The digestion was terminated by adding 10 ml RPMI 1640 containing 5% FBS, and the supernatant was discarded, followed by two more washes with HBSS buffer. The islets were spun down and treated with 0.25% trypsin–0.02% EDTA at 37°C for 5–10 min. The islets were then passed through a syringe with a 27-gauge needle to disperse into a cell suspension. After washing with PBS, the isolated cells were stained with fluorochrome-conjugated mAbs for flow cytometric analysis.

Histology of pancreatic tissues
Pancreatic tissues were fixed with 10% buffered formalin, embedded in paraffin, and sectioned at a thickness of 5 μm, stained with hematoxylin and eosin, and examined under light microscopy.

Diagnosis of diabetes
Mice were screened for glycosuria and confirmed by a blood glucose of >250 mg/dl (13.9 mmol/L).

Cohousing
MyD88−/−NY8.3NOD mice or WT NY8.3NOD mice (4 wk old) were cohoused with an equal number of age- and sex-matched NOD mice. All the mice were monitored for glycosuria twice weekly, and the experiments were terminated at 20 and 30 wk after birth for MyD88−/−NY8.3NOD or WT NY8.3NOD and WT NOD mice, respectively, unless the mice developed diabetes.

Bacteria OT
Fecal samples were collected from diabetes-protected MyD88−/−NY8.3NOD mice, cohoused with NOD mice for >3 mo, and orally fed to the sex-matched 4-wk-old MyD88−/−NY8.3NOD mice, two to three times weekly for three consecutive weeks. All the mice were monitored for glycosuria twice weekly. We randomly selected diabetes-free MyD88−/−NY8.3NOD mice (Fig. 6 B) as breeders and observed for diabetes in their progeny, also using the progeny from the breeders without OT as controls. In some experiments, NOD mice (1.5–2-mo-old females) were gavaged with L. goodfellowii or B. theta (∼109 bacteria/mouse) daily for 5 d. APCs from spleens or MLNs, PPs and the GALT were used for antigen-presentation assays ex vivo.

Extraction of gut bacterial DNA
Fecal samples from WT NY8.3NOD and MyD88−/−NY8.3NOD mice were collected biweekly starting from 1-mo-old mice and stored at −20°C. Bacterial DNA was ex-
tracted as previously described (Peng et al., 2014). In brief, the fecal samples (~15–25 mg/mouse) were resuspended in 300 µl TE (10 mM Tris and 1 mM EDTA, pH 8) and incubated for 1 h at 37°C in the presence of 7.5 µl SDS (0.5%) and 3 µl proteinase K (20 mg/ml). One volume of phenol/chloroform/isoamyl alcohol (25:24:1), 200 µl of 20% SDS, and 0.3 g of zirconium/silica beads (0.1 mm; Biospec Inc.) were added, and samples were mixed with a Mini-bead-beater (Biospec) for 2 min. The sample was then mixed with 820 µl phenol/chloroform/isoamyl alcohol (25:24:1) and centrifuged, and the aqueous layer was collected into a new tube. The bacterial DNA was precipitated with 0.6 volume of isopropanol, washed with 70% ethanol, air dried, and resuspended in 100 µl of sterile water.

16S rRNA sequencing and microbiota classification

The V4 region of the bacterial 16S ribosomal gene was amplified from each DNA sample with barcoded broadly conserved bacterial primers (Table 2). The PCR products were purified with a gel extraction kit (QIAGEN) and quantified with a spectrophotometer (Nanodrop), and equimolar
Quantification of Fusobacteria and L. goodfellowii by qPCR

Bacterial DNA was extracted as described in the Extraction of gut bacterial DNA section from fecal pellet or oral swab samples from 6–7-wk-old MyD88<sup>−/−</sup>NY8.3NOD and WT NY8.3NOD mice. qPCR was performed using a qPCR detection system (iQ5; Bio-Rad Laboratories) according to the manufacturer’s instructions. The relative abundance of Fusobacteria in the selected samples from three time points (no insulitis at 6 wk, mid-insulitis at 10 wk, and insulitis at >13 wk before diabetic) was quantified by qPCR.

Quantification of intestinal antimicrobial peptides by qPCR

Approximately 3-cm fragments from the ileum of small intestine and the area adjacent to the cecum of large intestines were obtained from 6–7-wk-old MyD88<sup>−/−</sup>/NY8.3NOD and WT NY8.3NOD mice. Total RNA was extracted from the gut fragments with TRizol and reverse transcribed to cDNA using a SuperScript III First-strand synthesis kit with random hexamers (Invitrogen). qPCR was performed with the specific primers for Reg3β, Reg3γ, C-reactive protein–ductin, RELMβ, and DEFCR–rs-10 (Vaishnava et al., 2008). The relative mRNA levels of these peptides were determined using the 2<sup>−ΔΔCt</sup> method by normalization with the housekeeping gene GAPDH (Table 2).

Identification and synthesis of mimic peptides

The IGRP 206–214 peptide sequence was pBLAST searched against the nonredundant protein sequences database within bacterial families, and peptides with high homology were identified. The microbial peptide mimics (Table 1) were synthesized and purified with HPLC by the Yale Keck Facility.

Culture of anaerobic bacteria

L. goodfellowii (HM-12; BEI Resources), B. theta (provided by A. Goodman and A. Wexler, Yale University, New Haven, CT), B. dorei (BEI Resources), and L. reuteri (BEI Resources) were grown in MTGE Anaerobic Enrichment Broth (Anaerobe Systems) overnight. For heat-killed bacteria, the bacterial pellet was resuspended in sterile 1× PBS and heated at 65°C for 60 min. The bacterial lysates were then used to stimulate the NY8.3 CD8<sup>+</sup> T cells followed by intracellular cytokine (ICC) analysis.

Translation of rMgt and expression and purification of truncated rMgt protein

The coding region of Mgt (GenPept accession no. WP_006806773) from L. goodfellowii was amplified with PCR from genomic DNA from L. goodfellowii with specific primers (Table 2) and then cloned into EcoR I/ Xho I digested pET23b<sup>+</sup> (EMD Millipore). The recombinant vector was confirmed with DNA sequencing by the Yale Keck Facility. The in vitro translation of Mgt was performed in an E. coli High-yield Protein Expression System (S30 T7; Promega) according to the manufacturer’s instructions. Empty pET23b<sup>+</sup> was used as a negative control. The truncated rMgt was ex-
pressed and purified by Detai Biologics. In brief, the coding region of Mgt was modified by removing two transmembrane fragments (355–374 and 382–404) and replacing the rare codons for E. coli and cloned into pET43.1a. The recombinant protein was obtained by refolding insoluble inclusion bodies and purifying by affinity column chromatography. The single-band purity was confirmed by both SDS-PAGE and Western blotting.

**Generation of BMDCs, APC isolation, and NY8.3**

**CD8+ T cell purification**

BMDCs were generated from BM cells of 2-mo-old NOD mice. The BM cells were cultured in the presence of 25 ng/ml GM-CSF and 25 ng/ml IL-4 in RPMI 1640 complete medium supplemented with 5% heat-inactivated FBS. Culture medium was replenished every 2 d. On day 5, adherent and loosely adherent cells were harvested. These cells were ~70% CD11c+ DCs by FACS analysis.

Peripheral APCs in this study refer to T cell–depleted immune cells (CD11c+, CD11b+, and CD19+ cells) and were isolated from spleen, MLN, and PP of 2-mo-old female NOD mice by depleting CD4+ and CD8+ T cells with hybridoma isolated from spleen, MLN, and PP of 2-mo-old female NOD mice by depleting CD4+ and CD8+ T cells with hybridoma supernatant and magnetic beads.

CD8+ T cells were purified from spleen of 5–8-wk-old WT NY8.3NOD or MyD88−/−NY8.3NOD mice by negative selection with magnetic beads according to the manufacturer’s instructions (QIAGEN). The purity was routinely 90–95% as verified by flow cytometry.

**Cell proliferation assay**

Splenocytes or purified CD8+ T cells from WT NY8.3NOD or MyD88−/−NY8.3NOD mice were cultured in triplicate (10^6 cells/well) with different concentrations of IGRP, B15-23 peptide or bacterial peptide mimics at different concentrations for 4 d. [3H]Thymidine was added during the last 18 h of a 4-d culture. Proliferation was measured by [3H]thymidine incorporation, and the data are presented as a stimulation index, which is the mean cpm in the presence of antigen/the mean cpm in the absence of antigen.

**MHC restriction assay**

Purified splenic NY8.3 CD8+ T cells were cultured in triplicate (10^6 cells/well) with different concentrations of IGRP or W15944 peptide in the presence of irradiated splenic APCs from NOD (Kb) or C57BL/6 (Kb) mice. [3H]Thymidine was added in the last 16 h of 4-d culture. Proliferation was measured by [3H]Thymidine incorporation, and the data are presented as a stimulation index, which is the mean cpm in the presence of antigen/the mean cpm in the absence of antigen.

**CTL killing assays**

Target P815 cells (10^4 cells/tube) were labeled with PKH-26 followed by co-culturing with purified NY8.3 CD8+ T cells, as effector cells, from 6–7-wk-old WT NY8.3 mice at different ratios in the absence or presence of IGRP or W15944 (0.2 µg/ml) in 200 µl at 37°C for 16–18 h. Cells were stained with TOPRO-3 iodide before analysis by flow cytometry. The cytotoxicity was calculated as the percentage of apoptotic cells shown as double positive for TOPRO-3 iodide and PKH-26.

**Supercolonization of WT NY8.3 mice with B. theta or L. goodfellowii**

1-mo-old WT NY8.3NOD mice were orally gavaged with either B. theta or L. goodfellowii (∼10^9 bacteria/mouse) daily for 30 consecutive days, unless the mice developed diabetes.

**ICC, granzyme B, MIP-1β, and IFN-γ secretion assay**

ICC staining was performed according to the protocol provided by eBioscience. In brief, 1–2 × 10^5 cells/ml splenocytes from WT NY8.3 or MyD88−/−NY8.3 mice were stimulated with anti-CD3 (clone 2C-11) and anti-CD28 (clone 37N51) antibodies, IGRP206–214, peptide mimics, heat-killed bacteria, and APCs either pulsed with heat-killed bacteria or directly isolated from bacteria-supercolonized NOD mice or rMgt overnight, followed by further stimulation with 50 ng/ml PMA (Sigma-Aldrich) and 500 ng/ml ionomycin (Sigma-Aldrich) in the presence of Golgi-plug (eBioscience) for an additional 4 h. 10^6 cells/ml splenocytes from G9Ca−/−NOD mice were stimulated with insulin B15–23 peptide (G9G) and the bacterial peptide mimics in a similar assay. The cells were then stained with antibodies to surface markers before fixation and permeabilization. Fc receptors were blocked with 2.4G2 Fc-blocking antibody before staining with fluorochrome-labeled antibody to detect ICCs or cytolytic protein (IFN-γ and granzyme B). Some of the supernatants were used for ELISA to measure the concentration of MIP-1β or IFN-γ.

In some experiments, 1–2 × 10^5 purified NY8.3 CD8+ T cells were incubated with 10^5 cells BMDCs or 1–5 × 10^5 APCs, in 300 µl, in the presence of 10^7 CFU/500 µl heat-killed bacterial lysates (L. goodfellowii or B. theta), translated Mgt protein (1 µl of the protein lysate; empty vector as control), or 1 µg of purified truncated Rmg protein obtained from E. coli by the pET43.1a expression vector (carrier protein BSA as control) overnight, followed by further stimulation with PMA and ionomycin in the presence or absence of Golgi-plug for an additional 4 h. The cells were used for ICC staining in the cell culture.
in the presence of Golgi-plug, and the culture supernatants without Golgi-plug were tested for MIP-1β secretion by an ELISA kit (R&D Systems).

To test whether APCs could present antigens from the bacteria, 2 × 10^5 APCs from spleen, MLN, and PP were isolated from 6–8-wk-old naive NOD mice and pulsed with heat-killed *L. goodfellowii* or control *B. theta* lysates for 3 h at 37°C. After washing, the APCs were incubated with 10^5 purified NY8.3 CD8+ T cells from WT NY8.3 overnight in 300 µl with the cells were stained for use for ICC staining in the cell culture in the presence of Golgi-plug.

After supercolonization with the gut bacteria, 10^5 purified NY8.3 CD8+ T cells were incubated with purified APCs from spleen (10^6 cells), MLN (5 × 10^5 cells), or PP (1–2 × 10^5 cells) overnight in 300 µl without the addition of exogenous antigens. The supernatants before the addition of Golgi-plug were tested for MIP-1β and IFN-γ secretion by ELISA (R&D Systems), and after 4-h stimulation with PMA/ionomycin in the presence of Golgi-plug, the culture supernatants were tested for MIP-1β and IFN-γ secretion by ELISA (R&D Systems).

Adoptive transfer

Irradiated (600 rads) 1-mo-old NOD mice (both genders) were used as recipients in adoptive transfer experiments. Splenocytes from 6–7-wk-old WT NY8.3 or MyD88−/−NY8.3 mice were stimulated with IGRP206-214 peptide (10 ng/ml), W15944 (10 ng/ml or 500 ng/ml), or other peptide mimics (500 ng/ml) for 3 d at 37°C. 10^6 activated CD8+ T cells, purified with magnetic-activated cell-sorting beads, were injected into age- and sex-matched recipients. Recipients were screened for diabetes development by testing for glycosuria daily, and the experiments were terminated 20 d after the cell transfer unless the mice developed diabetes.

Immunization of mimic peptide in WT NY8.3 NOD mice

1-mo-old WT NY8.3 NOD mice were i.p. immunized once with W15944 or IGRP peptide (25 µg/mouse) together with Cpg (25 µg/mouse) as adjuvant. Control mice were injected with CpG (25 µg/mouse) only. Mice were screened for glycosuria daily, and the experiments were terminated 30 d after immunization unless the mice developed diabetes.

Statistical analysis

Statistical analysis was performed using Prism 6 (GraphPad Software). Diabetes incidence was compared using Wilcoxon or log-rank tests. Insulitis was analyzed by \( \chi^2 \) test. In vitro assays were analyzed with two-tailed Student’s t test or one- or two-tailed Mann Whitney test for statistical significance. Analysis of similarities (ANOSIM) was used to analyze β-diversity of taxonomic families of gut microbiota. For multiple comparisons, one-way or two-way ANOVA followed by Bonferroni test or Tukey’s posthoc test was performed. P-values <0.05 were considered significant.

ACKNOWLEDGEMENTS

We thank Drs. A. Wexler and A. Goodman for initial molecular modification of *L. goodfellowii* and for providing B. theta; Drs. F. Li, X. Yu, and H. Zhao for help with statistical analysis; G.M. Vijay for experimental assistance; and Dr. H. Ding for help with the truncated Mgt protein.

This work was supported by grants from the National Institutes of Health (DK088181, DK092882, DK100500, and P30 DK496735), the Iacocca Family Foundation, and the Juvenile Diabetes Research Foundation (2015-136). The authors declare no competing financial interests.

Submitted: 13 April 2016
Accepted: 5 August 2016

REFERENCES


